Novel allosteric Akt inhibitor (ALM301) Patent Protection Secured
February 4, 2016
Almac Discovery Secures Patent Protection for Novel allosteric Akt inhibitor (ALM301)
Craigavon, N.I., UK, – 2 February 2016 – Almac Discovery, a research driven oncology company that is dedicated to the discovery and development of novel and innovative approaches to the treatment of cancer, has announced that it has been granted patent protection (US Patent Number 9221838) for its novel therapeutic drug, ALM301, in the United States of America, the largest pharmaceutical market in the world. This adds to patent protection already granted in the European Union and a further 8 countries, strengthening the product’s protection globally.
ALM301 is a novel isoform specific allosteric inhibitor of Akt, a therapeutic target relevant for the treatment of a wide range of cancers. In addition, it has been shown that Akt inhibition could be valuable in overcoming resistance acquired by cancer patients being treated with current therapies.
About Almac Discovery
Almac Discovery is a research driven oncology company that is dedicated to the discovery and development of novel and innovative approaches to the treatment of cancer. Almac Discovery focuses on the discovery to preclinical stage seeking to partner programs at an early time point with the pharmaceutical industry. Exceptionally the company will undertake clinical development to an early stage before partnering. Almac Discovery is part of the Almac Group.